Phase II study in patients with primary TNBC randomized to T-FEC ( paclitaxel @ mg/m ( @ ) i.v. weekly for @ weeks , followed by @-fluorouracil @ mg/m ( @ ) , epirubicin @ mg/m ( @ ) , and cyclophosphamide @ mg/m ( @ ) every @ weeks for four cycles ) versus TR-FEC ( paclitaxel @ mg/m ( @ ) i.v. and everolimus @ mg PO weekly for @ weeks , followed by FEC ) .